Abstract

BackgroundThis study aimed to describe the clinical and biochemical features of Chinese patients with ornithine transcarbamylase deficiency (OTCD), and to investigate the mutation spectrum of OTC gene and their potential correlation with phenotype.MethodsSixty-nine patients with OTCD were enrolled between 2004 and 2019. Clinical and laboratory data were reviewed retrospectively from medical records.ResultsFifteen cases (13 males, 2 females) presented with early onset; 53 cases (21 males, 32 females) had late onset, and one female was asymptomatic. The median onset age was 1.5 years (range 1 day–56 years). Urine orotic acid levels were increased in all patients tested, while only 47.6% of patients showed decreased serum levels of citrulline. The peak plasma ammonia levels were higher in early-onset patients than in late-onset patients (P < 0.01). Fifty-four different mutations of OTC gene were identified and 18 of them were novel. R277W (10.6%) was the most common mutation, followed by G195R (4.6%) and A209V (3.0%). By June 2019, 41 patients had survived, 24 were deceased, and 4 were lost to follow-up. Among the survivors, 13 patients had received liver transplantation at a median age of 3 years, with a one-year survival rate of 100%. The mortality of OTCD is extremely high among patients with early onset (80.0% versus 24.5% in patients with late onset).ConclusionsThe evaluation of serum citrulline level is of limited value in diagnosis of OTCD, while urine orotic acid detection and genetic testing are more helpful.

Highlights

  • Ornithine transcarbamylase deficiency (OTCD, MIM #300461) is one of the most common urea cycle disorders and accounts for approximately half of the inherited urea cycle disorders

  • The diagnosis of ornithine transcarbamylase deficiency (OTCD) was based on clinical features, specific biochemical criteria, as well as molecular analysis

  • Diagnostic mode In this study, 15 patients underwent the newborn screening by MS/MS using blood citrulline as a biomarker

Read more

Summary

Introduction

Ornithine transcarbamylase deficiency (OTCD, MIM #300461) is one of the most common urea cycle disorders and accounts for approximately half of the inherited urea cycle disorders. 20% of heterozygous females present some neurocognitive disorders due to unfavorable random X-inactivation. The clinical picture of carrier females is highly diverse because of the extent of X-inactivation in hepatocytes [7]. The major symptoms include vomiting, apastia, lethargy, convulsion, muscle hypotonia, and coma. These symptoms can be precipitated or aggravated by high protein meals, fasting, infections, trauma, surgery, or childbirth [8]. This study aimed to describe the clinical and biochemical features of Chinese patients with ornithine transcarbamylase deficiency (OTCD), and to investigate the mutation spectrum of OTC gene and their potential correlation with phenotype

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call